Clinical Trials on Leukemia, T-Cell in Russian Federation

Total 769 results

Hoffmann-La Roche

Active, not recruiting

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Hungary, Australia, Taiwan, China, Denmark, Italy, Spain, Turkey, Japan, France, Korea, Republic of, Germany, Poland, Thailand, Egypt, Russian Federation, Austria, Ukraine, United Kingdom, Romania, Kazakhstan, Bosnia... and more
Janssen Research & Development, LLC

Completed

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Multiple Myeloma

Australia, France, Poland, United Kingdom, United States, Spain, Israel, Portugal, South Africa, Canada, Netherlands, Belgium, Singapore, Russian Federation, Czech Republic, Argentina, Austria
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER)

Non Small Cell Lung Cancer

Italy, United States, Spain, Germany, Korea, Republic of, Poland, Romania, Taiwan, Ukraine, France, Japan, Russian Federation, Austria, Israel, Greece, Brazil, Argentina, Turkey, Canada, Puerto Rico, China
GlaxoSmithKline

Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Multiple Myeloma

China, Korea, Republic of, Australia, Italy, Spain, United States, Brazil, Czechia, France, Germany, Greece, Israel, Japan, New Zealand, Poland, Russian Federation, Turkey, United Kingdom
GlaxoSmithKline

Active, not recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3)

Multiple Myeloma

United States, Australia, Spain, Bulgaria, Poland, Belgium, France, Germany, Italy, Hungary, United Kingdom, Greece, Russian Federation, Brazil, China, Korea, Republic of, Japan, Canada, Netherlands
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
Hoffmann-La Roche

Completed

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma (BRIM8)

Melanoma

United States, Israel, Italy, Spain, Belgium, United Kingdom, Austria, Czechia, France, Netherlands, New Zealand, Russian Federation, Australia, Canada, Croatia, Portugal, Germany, Ukraine, Switzerland, Argentina, Brazil, Ireland, N... and more
Boehringer Ingelheim

Completed

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain, Bulgaria, Serbia, United Kingdom, United States, Korea, Republic of, Malaysia, Vietnam, Poland, Egypt, Hungary, Ukraine, Brazil, Turkey, Japan, Portugal, Thailand, Philippines, Russian Federation, Italy, Mexico, Greece, Croatia, Chi... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Germany, Japan, China, Israel, Belgium, Italy, France, Taiwan, Thailand, Korea, Republic of, Malaysia, Spain, Hungary, Turkey, Portugal, India, Brazil, Poland, Australia, Russian Federation, Mexico, Puerto Rico, U... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

Carcinoma, Non-Small-Cell Lung

Canada, Germany, Italy, China, Belgium, United States, Taiwan, Israel, United Kingdom, Korea, Republic of, Sweden, Japan, Poland, Malaysia, Netherlands, Spain, Turkey, France, India, Mexico, Argentina, Brazil, Portugal, Russian Federation and more
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Participants With Metastatic Melanoma

Malignant Melanoma

Canada, Spain, United Kingdom, Hungary, Australia, Austria, Belgium, Ecuador, Estonia, Finland, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Slovenia, Sweden, Turkey, Brazil, India, Germany, Bosnia and Herzegovina and more
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
Novartis Pharmaceuticals

Completed

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Carcinoma, Non-Small-Cell Lung

Italy, Spain, Germany, Japan, Taiwan, Belgium, Netherlands, Singapore, Argentina, France, Israel, Sweden, Korea, Republic of, Lebanon, United Kingdom, United States, Austria, Mexico, Norway, Russian Federation
AbbVie

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

Giant Cell Arteritis (GCA)

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Romania, Russian Federation, Spain, Sweden, Switzerland, United...
Amgen

Completed

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)

Relapsed or Refractory Multiple Myeloma

France, Czechia, Sweden, United States, Greece, Spain, Finland, Romania, Germany, Japan, Netherlands, Turkey, Austria, Bulgaria, Lithuania, Russian Federation, Slovakia
Boehringer Ingelheim

Completed

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain, Germany, China, Israel, Denmark, Belgium, Switzerland, Croatia, Poland, Romania, South Africa, Czechia, Greece, Portugal, United Kingdom, India, Italy, Austria, Belarus, Ukraine, Russian Federation, France, Bulgaria, Georgia, Korea... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Japan, Canada, Netherlands, Denmark, Sweden, Korea, Republic of, Russian Federation, Greece
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

Hong Kong, Canada, Korea, Republic of, Belgium, Australia, United States, Taiwan, United Kingdom, Germany, Italy, Japan, Austria, Thailand, Peru, Ireland, Russian Federation, Philippines, France, Brazil, Chile, Argentina, Hungary, M... and more
AbbVie
Genentech, Inc.

Completed

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (Bellini)

Relapsed/Refractory Multiple Myeloma

United States, Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

Multiple Myeloma

Canada, United States, Belgium, Korea, Republic of, United Kingdom, Sweden, Italy, Denmark, Japan, Taiwan, China, Germany, Spain, France, Netherlands, Turkey, Russian Federation, Poland, Greece, Argentina, Brazil
GlaxoSmithKline

Active, not recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

Multiple Myeloma

Australia, Japan, Spain, Germany, Poland, Belgium, Israel, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, China, Brazil, Czechia, United States, Netherlands, United Kingdom, Greece, France
Karyopharm Therapeutics Inc

Active, not recruiting

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)

Multiple Myeloma

United States, United Kingdom, Australia, Israel, Canada, Belgium, Austria, Czechia, Serbia, India, France, Italy, Russian Federation, Bulgaria, Germany, Greece, Hungary, Poland, Romania, Spain, Ukraine
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Multiple Myeloma

France, Poland, Ukraine, Germany, Spain, Israel, Portugal, Slovenia, South Africa, Turkey, Greece, Estonia, Russian Federation, Hungary, Austria, Lithuania, Macedonia, The Former Yugoslav Republic of, Latvia, Croatia, Denmark, A...
Pfizer

Active, not recruiting

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Carcinoma, Non-Small-Cell Lung

Canada, Spain, United States, China, Korea, Republic of, United Kingdom, France, Czechia, Japan, Singapore, Taiwan, Australia, Netherlands, India, Turkey, Hong Kong, Argentina, Belgium, Germany, Italy, Mexico, Poland, Russian Federation
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)

Carcinoma, Non-Small-Cell Lung

United States, France, Canada, China, Israel, Belgium, United Kingdom, Italy, Argentina, Japan, Taiwan, Thailand, Korea, Republic of, Malaysia, Poland, Australia, Spain, Netherlands, Hungary, Turkey, Germany, India, Brazil, Russian Federation and more
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
Amgen

Recruiting

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Chemotherapy-induced Thrombocytopenia

United States, Spain, Turkey, Argentina, Greece, Austria, Brazil, Bulgaria, Chile, Colombia, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Ukraine, Hungary
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

Australia, Poland, United Kingdom, United States, Belgium, Germany, Spain, Argentina, Portugal, Bulgaria, Romania, Serbia, Turkey, Ukraine, Japan, Greece, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia, Croatia, Ge... and more
Millennium Pharmaceuticals, Inc.

Completed

A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

United States, France, Norway, Spain, Israel, United Kingdom, Italy, Australia, Germany, Greece, Canada, Czechia, Turkey, Russian Federation, Denmark, Sweden, Belgium, Netherlands
Centus Biotherapeutics Limited

Completed

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA)

Carcinoma, Non-Small-Cell Lung

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Georgia, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Peru, Philippines, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, Ukrain... and more
Novartis Pharmaceuticals

Completed

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)

Malignant Melanoma

Canada, Italy, Czechia, Australia, France, Greece, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Slovakia, Slovenia, Japan, Turkey, Argentina, Finland, Norway, Brazil, Latvia, Lithuania, Poland, Portugal
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower150)

Carcinoma, Non-Small-Cell Lung

United States, Spain, France, Belgium, Australia, Germany, Argentina, Japan, Brazil, Italy, Singapore, Russian Federation, Taiwan, Netherlands, Peru, Chile, Latvia, Ukraine, Mexico, Lithuania, Slovakia, Bulgaria, Portugal, Austria, Swit... and more
Amgen

Completed

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

Canada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Carcinoma, Non-squamous Non-small-cell Lung

Poland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
AbbVie
Radiation Therapy Oncology Group

Completed

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Glioblastoma | Gliosarcoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Germany, Hong Kong, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian Federation, Singapor... and more
Novartis Pharmaceuticals

Active, not recruiting

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i)

Melanoma

Italy, Czechia, Germany, Hungary, Canada, United States, Argentina, Australia, Austria, France, Israel, Russian Federation, Spain, Sweden, United Kingdom, Thailand, Belgium, Brazil, Greece, Switzerland, Mexico, Netherlands, Denmark, C... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Taiwan, Belgium, Denmark, Switzerland, Argentina, Israel, Italy, Croatia, United Kingdom, Korea, Republic of, Russian Federation, Slovakia, Japan, Bulgaria, Poland, Hungary, Australia, Turkey, Peru, Chile, Mexico, Czech... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate548)

Brain Neoplasms

United States, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
Millennium Pharmaceuticals, Inc.

Completed

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States, France, Korea, Republic of, Canada, Belgium, New Zealand, Russian Federation
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

Carcinoma, Non-Small-Cell Lung

United States, Denmark, Taiwan, China, Canada, Spain, Japan, Germany, United Kingdom, Brazil, India, Korea, Republic of, Australia, Italy, Norway, Israel, Greece, Turkey, Netherlands, Austria, Belgium, Hong Kong, Poland, Puerto Rico, Russian... and more
Pfizer

Completed

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Metastatic or Unresectable Cutaneous Melanoma

United States, Spain, Canada, Italy, United Kingdom, Germany, Korea, Republic of, France, Australia, Czechia, Russian Federation, Turkey, Israel, Netherlands, Greece, Hungary, Japan, Portugal, Argentina, Austria, Belgium, Brazil, Po... and more
Millennium Pharmaceuticals, Inc.

Completed

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

Hematopoietic Stem Cells

United States, Spain, Taiwan, Australia, Canada, Singapore, Korea, Republic of, Mexico, Switzerland, Japan, Germany, Norway, Israel, Russian Federation, Hungary, United Kingdom, Italy, Romania, Brazil, France, Austria, Belgium, Port... and more
Pfizer
Merck Sharp & Dohme LLC

Active, not recruiting

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Melanoma

France, United States, Hungary, Italy, Spain, Czechia, Belgium, Germany, New Zealand, Canada, Austria, Israel, Poland, Russian Federation, Turkey, Switzerland, South Africa, Slovakia, United Kingdom, Ukraine, Brazil, Argentina, Bulg... and more
AstraZeneca

Recruiting

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)

Carcinoma, Non-Small-Cell Lung

United States, China, Israel, United Kingdom, Korea, Republic of, Canada, Italy, Poland, Spain, Belgium, Netherlands, Japan, Germany, Brazil, France, Turkey, Russian Federation, Greece, Australia, Puerto Rico
Celgene

Completed

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (OPTIMISMM)

Multiple Myeloma

United States, Spain, United Kingdom, Italy, Israel, Portugal, Germany, Turkey, Greece, Ireland, Austria, Norway, Netherlands, Denmark, Poland, France, Russian Federation, Canada, Finland, Japan, Puerto Rico, Sweden
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)

Brain Cancer

United States, Canada, Belgium, Spain, Australia, Netherlands, United Kingdom, Denmark, Norway, Japan, Sweden, France, Poland, Austria, Germany, Israel, Italy, Russian Federation, Switzerland
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

Poland, Romania, Ukraine, Chile, Canada, United States, Argentina, China, Czechia, Estonia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Norway, Peru, Russian Federation, Spain, Thailand, Turkey, United...
Bristol-Myers Squibb
AbbVie

Completed

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

Multiple Myeloma

United States, Australia, Austria, Belgium, Canada, Czechia, Germany, Greece, Hungary, Ireland, Israel, Italy, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland, Turkey, United Kingdom
Pfizer

Completed

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Carcinoma, Non-Small-Cell Lung

United States, Canada, Spain, China, Brazil, United Kingdom, Japan, Poland, Australia, France, Ireland, Taiwan, Italy, Germany, Netherlands, Korea, Republic of, Bulgaria, Greece, Hong Kong, Hungary, Russian Federation, Sweden

Clinical Trials on Leukemia, T-Cell in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations